Docetaxel and Cisplatin as First-Line Treatment for Patients with Metastatic Esophageal Cancer: A Pilot Study
| Autor: | Dieter K. Hossfeld, Rainer Lipp, Lutz Edler, Johann Popp, Gunter Schuch, Birte Andritzky, Eckart Laack, Hartmut Horst, Iris Burkholder, Heinz Dürk, Michael Görn, Ina Boeters |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Pilot Projects Docetaxel Germany Internal medicine Antineoplastic Combined Chemotherapy Protocols Prevalence medicine Humans Aged Cisplatin Chemotherapy Taxane business.industry Cancer Hematology Middle Aged Esophageal cancer medicine.disease Regimen Treatment Outcome Lymphatic Metastasis Adenocarcinoma Female Taxoids business medicine.drug |
| Zdroj: | Oncology Research and Treatment. 28:647-650 |
| ISSN: | 2296-5262 2296-5270 |
| DOI: | 10.1159/000089102 |
| Popis: | Background: We investigated the combination of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic esophageal cancer. Patients and Methods: 16 chemotherapy-naive patients with distant metastases were included in the study (15 male, 1 female; median age: 58.5 years (range 37-69); median ECOG performance status: 1). 11 patients (69%) had esophageal cancer, and 5 patients (31%) had cancer of the gastroesophageal junction. Patients received docetaxel 75 mg/m2 and cisplatin 80 mg/m2 on day 1 every 3 weeks. A total of 55 chemotherapy cycles was administered. The median number of cycles was 3 (range 1-6). Results: The overall response rate was 31.3%. 4 out of 10 patients (40%) with squamous cell carcinoma and 1 out of 5 patients (20%) with adenocarcinoma responded to chemotherapy. The median overall survival was 29.6 weeks, and the median progression-free survival was 18.6 weeks. Hematological and non-hematological toxicities were moderate (neutropenia WHO grade III/IV: 42.9%, alopecia grade II/III: 64.3%, nausea/vomiting grade II/III: 57.2%, neurotoxicity grade II: 14.3%). Conclusion: The combination of docetaxel and cisplatin is an active regimen with moderate toxicity in the treatment of patients with metastatic esophageal cancer. This pilot study demonstrates the feasibility of a combination treatment containing a taxane and cisplatin in metastatic esophageal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|